Clinical trial
Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy
NCT00191841 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191841 |
|---|---|
| Title | Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy |
| Official title | Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | gemcitabine, Cisplatin |
| Enrollment | 50 |
| Start date | Dec 1, 2002 |
| Completion | Feb 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 24, 2006 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: